Wednesday, July 8, 2026

pharma · Polycythemia Vera · Ulcerative Colitis Chronic Moderate · PTGX

Protagonist Therapeutics

Protagonist Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

7707 Gateway Blvd, Suite 140, Newark, California 94560, US HQ
2006 Founded
153 Employees
Public company Type
PTGX · NYSE Ticker
Company details
Status
Public
HQ
7707 Gateway Blvd, Suite 140, Newark, California 94560, US
Founded
2006
Employees
153
Programs
13
Drugs
5
Patents
33
Intelligence · Clinical Programs

Protagonist Therapeutics projects

5 ClinicalTrials.gov programs sponsored by Protagonist Therapeutics.

Protagonist Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. PN-232

    Protagonist Therapeutics, Inc

    Healthy Subjects

    phase 1 small molecule completed

    1 trial
  2. PN-235

    Protagonist Therapeutics, Inc

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  3. PN-881 Oral Solution

    Protagonist Therapeutics, Inc

    Healthy Volunteer

    phase 1 small molecule active

    1 trial
  4. PTG-100

    Protagonist Therapeutics, Inc

    Celiac Disease

    phase 1 small molecule completed

    1 trial
  5. PTG-300

    Protagonist Therapeutics, Inc

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Protagonist Therapeutics have?

5 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.